Lucid Diagnostics Provides Business Update and Second Quarter 2024 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/25/2026
- S&P 500, Nasdaq end down on tech stocks, investors weigh Iran moves
- Oil drops more than $2 despite new US sanctions on Iran
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- Wattmore and Eos Energy strike non-exclusive storage software deal
- Grand Canyon Education places CFO on leave amid stock trade probe
- S&P 500, Nasdaq end down on tech stocks, investors weigh Iran moves
- Funds sell $44bn in semiconductors on AI concerns
- RUM Group signs $13.7 billion GPU services deal, issues warrants
Cantor Fitzgerald Positive on Lucid Diagnostics Inc (LUCD) Following Earnings
August 13, 2024 2:57 PM EDTCantor Fitzgerald analyst Ross Osborn reiterated an Overweight rating and $3.00 price target on Lucid Diagnostics Inc (NASDAQ: LUCD).
The analyst comments "We reiterate our Overweight rating and 12-month price target of $3.00 on Lucid Diagnostics' (LUCD) shares following the company reporting 2Q24 operating results and providing... More
Needham Reiterates Buy Rating on Lucid Diagnostics Inc (LUCD)
August 12, 2024 4:47 PM EDTNeedham analyst Mike Matson reiterated a Buy rating and $2.50 price target on Lucid Diagnostics Inc (NASDAQ: LUCD).
The analyst comments "In 2Q24, EsoGuard test volume grew 30% sequentially and 43% Y/Y to 3,147. LUCD missed consensus revenue in 2Q24 and we note that LUCD has... More
